U.S. Markets closed

Genomic Health, Inc. (GHDX)

NASDAQ Global Select - NASDAQ Global Select Real Time Price. Currency in USD
Add to watchlist
30.14+0.40 (+1.34%)
At close: 4:00PM EDT

30.14 0.00 (0.00%)
After hours: 4:27PM EDT

People also watch
FMILMNXQGENSGENACOR

Genomic Health, Inc.

301 Penobscot Drive
Redwood City, CA 94063
United States
650-556-9300
http://www.genomichealth.com

SectorHealthcare
IndustryMedical Laboratories & Research
Full Time Employees846

Key Executives

NameTitlePayExercisedAge
Ms. Kimberly J. PopovitsChairman, Chief Exec. Officer and Pres1.33M143.84k58
Mr. G. Bradley ColeChief Financial Officer, Chief Operating Officer and Sec.817.44k401.12k61
Dr. Steven Shak M.D.Chief Scientific Officer769.18k341.4k66
Mr. James J. Vaughn R.Ph.Chief Commercial Officer628.8k63.8k54
Dr. Frederic G. Pla Ph.D.Chief Bus. & Product Devel. Officer786kN/A58
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype SEQ Liquid Select test, a non-invasive liquid biopsy test, which uses next-generation sequencing to identify and select actionable genomic alterations to quantify the presence and burden of cancer, as well as helps to predict the sensitivity or resistance to specific drugs for patients with certain late-stage cancers, such as lung, breast, colon, melanoma, ovarian, or gastrointestinal cancers. Its development stage pipeline products include Oncotype TRACK products for non-invasive tumor monitoring. The company offers its products through a network of distributors. Genomic Health, Inc. has a collaboration agreement with Epic Sciences, Inc. The company was founded in 2000 and is based in Redwood City, California.

Corporate Governance

Genomic Health, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 5. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 3; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.